Research Keyword: immunological markers

ABPA in post-tuberculosis lung disease: A diagnostic pitfall or genuine entity?

This article addresses confusion between two Aspergillus lung infections that commonly occur after tuberculosis: ABPA and CPA. While they have overlapping symptoms and test results, they require different treatments—ABPA responds to short-term steroids while CPA needs prolonged antifungal drugs. Importantly, giving steroids for misdiagnosed CPA can be harmful, so doctors should be cautious about diagnosing ABPA in tuberculosis survivors and consider CPA instead.

Read More »

The 2024 International Society for Human and Animal Mycology (ISHAM)-ABPA working group guidelines: Transforming diagnosis and management of ABPA

ABPA is a serious lung disease that develops when the body overreacts to a common fungus called Aspergillus. New international guidelines help doctors better diagnose and treat this condition, which affects many people with asthma and cystic fibrosis. The guidelines make diagnosis easier by using simpler tests and lowering the thresholds for detecting the disease, and they provide clear treatment plans depending on how severe each patient’s disease is. These updated standards are especially important in countries like India where ABPA is very common.

Read More »

ABPA in post-tuberculosis lung disease: A diagnostic pitfall or genuine entity?

After tuberculosis treatment, some patients develop fungal lung infections that can look very similar to an allergic fungal disease called ABPA. This editorial warns doctors that they need to be careful about diagnosing ABPA in tuberculosis patients because treating it with the wrong medications could make the fungal infection worse. The key difference is that true ABPA causes wheezing and asthma-like symptoms, while post-TB fungal infections cause cavities and scarring in the lungs.

Read More »
Scroll to Top